Fig. 8: Ellipticine and its analog phiKan 083 enhance the antifungal activity of FLC in vivo against C. albicans.

a An investigation was conducted on the survival of animals exposed to ellipticine against the wild-type SN152 in Galleria mellonella (n = 10 per group). b An investigation was conducted on the survival of animals exposed to ellipticine in a highly FLC-tolerant C. albicans strain, cmp1-aidΔ/cmp1-aidΔ in Galleria mellonella (n = 10 per group). c The fungal load in the kidneys of phiKan 083 was conducted in C. albicans SN152 was assessed. n = 12 mice. d The CFUs analysis of phiKan 083 was conducted in the C. albicans strain cmp1-aidΔ/cmp1-aidΔ. n = 12 mice. e The histopathological examination of phiKan 083 in the C. albicans SN152 involved staining the kidneys of mice with PAS, followed by the display of representative images from 3 biological repeats. f The histopathological examination of phiKan 083 in the C. albicans strain cmp1-aidΔ/cmp1-aidΔ involved staining the kidneys of mice with PAS, followed by the display of representative images from 3 biological repeats. g An investigation into the survival of Galleria mellonella larvae (n = 10 per group) infected with the C. albicans SN152, specifically focusing on the impact of phiKan 083 treatment. h An investigation into the survival of Galleria mellonella larvae (n = 10 per group) infected with the highly FLC-tolerant C. albicans strain cmp1-aidΔ/cmp1-aidΔ, specifically focusing on the impact of phiKan 083 treatment. Data were presented as mean ± SD (c, d). Log-rank (Mantel-Cox) test (a, b, g, h), two-tailed unpaired t-test (c, d). Source data are provided as a Source Data file.